Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease (NCT06370039) | Clinical Trial Compass
CompletedPhase 2
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
United States109 participantsStarted 2024-03-27
Plain-language summary
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
Who can participate
Age range18 Years – 74 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Subjects ≥18 and \<75 years of age
* Presence of moderate to severe dry eye disease (DED) in at least one eye
Key Exclusion Criteria:
* Presently using prescription eyedrops, except those used for dry eye disease, which must be discontinued 4 weeks prior
* Use of over-the-counter (OTC) eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing
* History or evidence of ocular infection within the previous 30 days
* Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months
* Allergic conjunctivitis requiring treatment within 30 days
* Unable to discontinue contact lens wear for 2 weeks prior and for the duration of the study
What they're measuring
1
Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scale